Operating Income - Prostatype Genomics AB (STO:PROGEN) - Alpha Spread
P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 0.019 SEK -7.32% Market Closed
Market Cap: 18.8m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prostatype Genomics AB
Operating Income Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Operating Income
-kr39.2m
CAGR 3-Years
-35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Operating Income
kr441.3m
CAGR 3-Years
25%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Operating Income
kr68.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Operating Income
-kr3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Operating Income
kr4.5B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Operating Income
kr264.6m
CAGR 3-Years
N/A
CAGR 5-Years
-11%
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Operating Income?
Operating Income
-39.2m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Operating Income amounts to -39.2m SEK.

What is Prostatype Genomics AB's Operating Income growth rate?
Operating Income CAGR 3Y
-35%

Over the last year, the Operating Income growth was -37%. The average annual Operating Income growth rates for Prostatype Genomics AB have been -35% over the past three years .

Back to Top